(PRWEB UK) 11 November 2014
Gardedam strategically integrates therapeutic focus, target family biophysics, drug discovery technology and expertise into an innovative pharmacological chaperone drug discovery approach, which synergizes to identify and develop small molecule candidates for clinical trials for neurodegenerative diseases. According to Dr. Gergely Tóth, CEO of Gardedam Therapeutics, ‘The funds raised through the crowdfunding campaign will support Gardedam’s preclinical drug discovery research, which target the DJ-1 protein that is linked to familial and sporadic Parkinson’s Disease and sporadic Alzheimer’s disease’.
About Gardedam Therapeutics
Gardedam (http://www.GardedamTherapeutics.com) is an early-stage pre-clinical biotechnology company focused on cutting-edge research to develop novel and curing therapies for Parkinson’s and Alzheimer’s disease.
Gergely Toth, PhD, MBA
CEO, Gardedam Therapeutics